Theravance Biopharma (NASDAQ:TBPH) Trading Up 5.7% on Analyst Upgrade

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) shares rose 5.7% during mid-day trading on Friday after BTIG Research raised their price target on the stock from $24.00 to $25.00. BTIG Research currently has a buy rating on the stock. Theravance Biopharma traded as high as $11.22 and last traded at $11.35. Approximately 77,972 shares traded hands during mid-day trading, a decline of 71% from the average daily volume of 268,919 shares. The stock had previously closed at $10.73.

A number of other research analysts have also recently commented on TBPH. Jones Trading upgraded Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective on the stock in a report on Tuesday, June 17th. Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "buy" rating in a research note on Saturday, June 21st. Three research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $16.60.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now directly owns 370,038 shares of the company's stock, valued at approximately $3,330,342. This represents a 1.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 6.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Theravance Biopharma

Several institutional investors have recently modified their holdings of the company. Rhumbline Advisers raised its stake in Theravance Biopharma by 3.8% in the first quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company's stock valued at $556,000 after buying an additional 2,293 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Theravance Biopharma by 121,993.7% in the first quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company's stock valued at $1,554,000 after purchasing an additional 174,451 shares in the last quarter. Jane Street Group LLC increased its stake in Theravance Biopharma by 169.2% in the first quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company's stock valued at $1,258,000 after purchasing an additional 88,540 shares during the last quarter. Park West Asset Management LLC raised its holdings in Theravance Biopharma by 0.6% during the first quarter. Park West Asset Management LLC now owns 1,804,244 shares of the biopharmaceutical company's stock worth $16,112,000 after purchasing an additional 11,256 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new stake in shares of Theravance Biopharma during the 1st quarter worth approximately $101,000. 99.10% of the stock is owned by hedge funds and other institutional investors.

Theravance Biopharma Trading Up 5.8%

The company's 50 day moving average is $9.94 and its 200 day moving average is $9.50. The stock has a market capitalization of $567.50 million, a price-to-earnings ratio of -9.61 and a beta of -0.09.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). The firm had revenue of $15.39 million for the quarter, compared to analyst estimates of $28.08 million. Theravance Biopharma had a negative return on equity of 32.37% and a negative net margin of 89.38%. Analysts anticipate that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.